Institution Directory

Clinical trials at NYU Langone Health

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 4:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1138

Shown on this page

Current sort

Live official records

Conditions: Lower Extremity Acute Limb Ischemia, LE ALI
Interventions: Indigo Aspiration System; Device
Lead sponsor: Penumbra Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 35
States / cities: Scottsdale, Arizona • San Diego, California • Ventura, California + 31 more

Conditions: Sudden Unexplained Death Syndrome, Sudden Unexplained Death in Childhood
Interventions: Biospecimin Collection; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 11 Months to 100 Years
Enrollment: 1,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid
Interventions: Semaglutide Pen Injector, Placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Baltimore, Maryland • Fall River, Massachusetts • New York, New York + 1 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: SIM0500; Drug
Lead sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 9
States / cities: Phoenix, Arizona • Orange, California • Jacksonville, Florida + 5 more

Conditions: Metastatic Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Unclassified Renal Cell Carcinoma
Interventions: Nephrectomy, Nivolumab, Patient Observation, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 819 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2031
U.S. locations: 396
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 293 more

Conditions: Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue, Clear Cell Sarcoma of Soft Tissue, Ewing Sarcoma, Hepatoblastoma, Hepatocellular Carcinoma, Osteosarcoma, Recurrent Adrenal Cortical Carcinoma, Recurrent Alveolar Soft Part Sarcoma, Recurrent Clear Cell Sarcoma of Soft Tissue, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Kidney Wilms Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Recurrent Renal Cell Carcinoma, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Medullary Carcinoma, Refractory Adrenal Cortical Carcinoma, Refractory Alveolar Soft Part Sarcoma, Refractory Clear Cell Sarcoma of Soft Tissue, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Primary Malignant Central Nervous System Neoplasm, Refractory Renal Cell Carcinoma, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory Thyroid Gland Medullary Carcinoma, Refractory Wilms Tumor, Renal Cell Carcinoma, Rhabdomyosarcoma, Soft Tissue Sarcoma, Solid Neoplasm, Thyroid Gland Medullary Carcinoma, Wilms Tumor
Interventions: Cabozantinib, Cabozantinib S-malate, Pharmacological Study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 30 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 142
States / cities: Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 104 more

Conditions: Cervical Cancer
Interventions: Sacituzumab Tirumotecan, Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 686 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 38
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 35 more

Conditions: Neoplasm Metastasis
Interventions: Docetaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine, Atezolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2027
U.S. locations: 49
States / cities: Duarte, California • Redondo Beach, California • San Francisco, California + 42 more

Conditions: Endometrial Cancer
Interventions: Sacituzumab tirumotecan, Doxorubicin, Paclitaxel, Nab-paclitaxel, Rescue medications; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 43
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 39 more

Conditions: HER2-positive Advanced Solid Tumor
Interventions: DB-1303/BNT323, Pertuzumab Injection, Ritonavir, Itraconazole; Biological · Drug
Lead sponsor: DualityBio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 796 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 35
States / cities: Cerritos, California • Los Angeles, California • San Diego, California + 29 more

Conditions: Infectious Disease
Interventions: No intervention; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Tucson, Arizona • Palo Alto, California • San Francisco, California + 16 more

Conditions: Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg), Placebo to match CK-4021586; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 26
States / cities: Fairhope, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more

About this NYU Langone Health institution page

What this page lists: ClinicalTrials.gov records that list NYU Langone Health in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at NYU Langone Health

Filter and sort this campus

Live official records

A Study of Patients With Lower Extremity Acute Limb Ischemia to Remove Thrombus With the Indigo™ Aspiration System (STRIDE II)

Sudden Unexplained Death in Childhood (SUDC) Registry

GLP-1R Agonist Treatment for Opioid Use Disorder

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

An International Observational Study of Adults With Acute Infection

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

About this NYU Langone Health institution page